Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Inclusion Criteria: * All patients must have a diagnosis of COPD and the following spirometric criteria: * Visit 1 (Screening) and Visit 2: Patients must have relatively stable, moderate to severe airway obstruction with an FEV1 ≤65% of predicted normal and FEV1 ≤70% of FVC * Male or female patients 40 years of age or older * Patients must have a smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year * Patients must be able to perform pulmonary function tests and maintain records during the study period as required in the protocol * Patients must be able to be trained in the proper use of an MDI (metered dose inhaler) and the Respimat® inhaler * All patients must sign an Informed Consent Form prior to participation in the trial Exclusion Criteria: * Patients with significant diseases other than COPD will be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study * Patients with clinically relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded * All patients with a SGOT (serum glutamic oxaloacetic transaminase) \>80 IU/L, SGPT (serum glutamic pyruvic transaminase) \>80 IU/L, bilirubin \>2.0 mg/dL or creatinine \>2.0 mg/dL will be excluded regardless of the clinical condition * Patients who have a total blood eosinophil count ≥600/mm3 * Patients with a recent history (i.e., one year or less) of myocardial infarction * Patients with a recent history (i.e., three years or less) of heart failure or patients with any cardiac arrhythmia requiring drug therapy * Patients with a history of cancer, other than treated basal cell carcinoma, within the last 5 years * Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis * Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of a thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1 * Patients with a history of asthma or allergic rhinitis * Patients with a history of and/or active alcohol or drug abuse * Patients with known active tuberculosis * Patients with an upper or lower respiratory tract infection or COPD exacerbation in the 6 weeks prior to the Screening Visit (Visit 1) or during the baseline period * Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction * Patients with known narrow-angle glaucoma * Patients with current significant psychiatric disorders * Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy * Patients who are being treated with cromolyn sodium or nedocromil sodium * Patients who are being treated with antihistamines for any excluded allergic conditions * Patients using oral corticosteroid medication at unstable doses (i.e., less than 6 weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day * Patients who initiated use of an inhaled steroid or changed doses less than 6 weeks prior to the Screening Visit (Visit 1) or during the baseline period * Patients who are being treated with beta-blocker medications, MAO (monoamine oxidase) inhibitors or tricyclic antidepressants. Beta blocker eye medications (e.g., Betoptic) for treatment of non-narrow angle glaucoma are allowed * Patients who have had changes in their therapeutic plan within the last 6 weeks prior to the Screening Visit (Visit 1) or during the baseline period * Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception * Patients with known hypersensitivity to anticholinergic drugs or any component of the ipratropium bromide/salbutamol Respimat® solution (including BAC (Benzalkonium chloride) and EDTA (Ethylenediaminetetraacetic acid)) or the ipratropium bromide/salbutamol MDI components * Previous participation in this study * Patients who are currently participating in another study